ExpreS2ion Biotech Holding Feed

2026-01-20 14:00:00 ExpreS2ion Biotechnologies: Subscriber Action Required: ExpreS2ion Press Release Distribution Moves to MFN

2026-01-19 10:26:29 ExpreS2ion Biotechnologies: ExpreS2ion to Participate in Key Investor Event in January 2026

2025-12-19 11:45:14 ExpreS2ion Biotechnologies: ExpreS2ion Reports Updated Immunogenicity Data from First Three Patients and DSMB Recommendation to Progress ES2B-C001 Phase I Trial to Next Dose Cohort 16,56 SEK | 0,00% | 0,35 MSEK

2025-11-13 08:30:00 ExpreS2ion Announces Financial Results for the First Nine Months and Third Quarter of 2025 18,74 SEK | +2,29% | 0,50 MSEK

2025-11-12 14:20:34 Correction: ExpreS2ion and Serum Institute of India Enter Definitive Licensing Agreement for Malaria Vaccines 18,32 SEK | +9,05% | 2,03 MSEK

2025-11-12 12:29:10 ExpreS2ion and Serum Institute of India Enter Definitive Licensing Agreement for Malaria Vaccines 18,32 SEK | +9,05% | 2,03 MSEK

2025-11-10 10:00:00 Oxford-Led Malaria Vaccine Trials Using ExpreS2ion Platform Advance Through Clinical Phases 17,46 SEK | +2,11% | 0,48 MSEK

2025-11-07 14:00:00 ExpreS2ion Hereby Changes Certified Advisor to Redeye 17,10 SEK | +3,01% | 0,14 MSEK

2025-11-03 14:00:00 ExpreS2ion to Participate in Key Investor and Industry Events in November 2025 17,06 SEK | +0,83% | 0,17 MSEK

2025-10-08 14:00:00 VICI-Disease Consortium Finalizes Nipah Vaccine Antigen, Initiates Production Phase 19,48 SEK | -2,40% | 0,19 MSEK

2025-10-06 16:12:46 ExpreS2ion Biotechnologies: Warrants of Series TO 11 Were Exercised to Approximately 88.5 Percent, ExpreS2ion Receives Approximately SEK 10.4 Million and Resolves on Directed Issues to Guarantors 20,50 SEK | -3,53% | 0,10 MSEK

2025-09-15 08:16:19 ExpreS2ion Obtains Top Guarantee Commitments and Subscription Commitments for Warrant Program TO 11, Reflecting Continued Support and Reinforcing Funding 18,00 SEK | -5,46% | 0,45 MSEK

2025-09-12 21:02:31 ExpreS2ion Announces TO 11 Warrant Exercise Price and Start of Exercise Period

2025-09-12 10:00:00 ExpreS2ion to Present in Upcoming Investor Events 19,04 SEK | -7,35% | 0,49 MSEK

2025-09-04 08:45:00 ExpreS2ion Reports First Immunogenicity Data from HER2 Breast Cancer Vaccine ES2B-C001 Phase I Trial 23,00 SEK | +5,99% | 0,88 MSEK

2025-09-02 11:00:00 ExpreS2ion Biotech Highlights CEO Presentations at Økonomisk Ugebrev and ProHearings Investor Events 20,60 SEK | -8,44% | 0,57 MSEK

2025-08-27 15:15:00 ExpreS2ion Biotech Announces Analysguiden Publishes Updated Equity Research Report; Price Target Maintained at SEK 75 23,85 SEK | +5,76% | 0,30 MSEK

2025-08-21 14:00:00 ExpreS2ion Biotech Announces Pareto Securities Analyst Note on Q2 2025 Results; Buy Rating Maintained with Price Target at SEK 303 23,90 SEK | +6,46% | 0,30 MSEK

2025-08-21 08:30:00 ExpreS2ion Announces Financial Results for the First Half and Second Quarter of 2025 23,90 SEK | +6,46% | 0,30 MSEK

2025-08-15 11:00:00 ExpreS2ion to Present in Upcoming Investor Events 23,50 SEK | -6,75% | 0,27 MSEK

2025-07-18 11:50:00 ExpreS2ion Highlights Strategic Relevance of GHIT-Funded Malaria Vaccine Development Through Ownership in AdaptVac 24,95 SEK | +8,95% | 0,29 MSEK

2025-07-07 10:10:00 ExpreS2ion enters strategic agreement with DTU for access to the Computerome supercomputer 27,00 SEK | +3,05% | 0,34 MSEK

2025-06-30 14:57:36 Austrian Regulatory Green Light Enables ADC Combination Testing and Phase I Site Expansion for ES2B-C001, a First-in-Class Breast Cancer Immunotherapy 24,95 SEK | +1,84% | 0,37 MSEK

2025-06-24 16:15:00 ExpreS2ion Biotech Announces Pareto Securities Analyst Note on First Patient Dosed in Phase I Trial 24,80 SEK | +3,33% | 0,40 MSEK

2025-06-23 14:03:57 ExpreS2ion announces dosing of first patient in Phase I clinical trial of ES2B-C001, its novel therapeutic breast cancer immunotherapy 24,00 SEK | +6,90% | 0,47 MSEK

2025-06-19 09:39:31 ExpreS2ion’s associated company AdaptVac to lead CEPI and EU funded USD 12.4 million consortium to develop novel filovirus vaccine 22,45 SEK | +5,15% | 1,46 MSEK

2025-05-28 11:30:00 Bulletin from the Annual General Meeting of Expres2ion Biotech Holding AB held on 28 May 2025 23,15 SEK | +0,65% | 0,70 MSEK

2025-05-23 13:29:53 ExpreS2ion Biotech Announces Analysguiden Publishes Equity Research Report 23,85 SEK | -14,67% | 7,58 MSEK

2025-05-21 11:13:43 ExpreS2ion Biotech Announces Pareto Securities Analyst Update on Q1 2025 Results and Clinical Trial Progress 23,60 SEK | +39,64% | 2,84 MSEK

2025-05-15 08:30:00 ExpreS2ion announces financial results for the first quarter of 2025 17,94 SEK | -3,13% | 0,14 MSEK

2025-05-13 12:15:00 ExpreS2ion files clinical trial amendment to enable combination testing of ES2B-C001 with antibody-drug conjugates and to expand the number of study sites 19,22 SEK | +1,05% | 0,24 MSEK

2025-05-09 13:00:00 ExpreS2ion to Present in Upcoming Investor Events 19,20 SEK | -1,64% | 0,29 MSEK

2025-05-01 12:40:00 ExpreS2ion annual report for 2024 published

2025-04-24 15:40:22 Notice to attend the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ) 19,50 SEK | -0,31% | 0,03 MSEK

2025-04-24 15:39:09 Kallelse till årsstämma i ExpreS2ion Biotech Holding AB (publ) 19,50 SEK | -0,31% | 0,03 MSEK

2025-04-15 08:45:00 ExpreS2ion signs Letter of Intent with WuXi Vaccines to initiate technology evaluation of ExpreS2ion’s proprietary production platform ExpreS2™ 19,58 SEK | -0,20% | 0,11 MSEK

2025-04-01 13:32:34 ExpreS2ion Provides Pipeline Update 19,90 SEK | -5,24% | 0,22 MSEK

2025-03-31 17:40:00 ExpreS2ion Announces Leadership Transition in R&D 19,90 SEK | -5,24% | 0,22 MSEK

2025-02-06 08:30:00 ExpreS2ion announces financial results for the fourth quarter of 2024 29,40 SEK | -1,34% | 0,61 MSEK

2025-01-09 11:00:00 ExpreS2ion to Present in Upcoming Investor and Scientific Events 23,60 SEK | -0,84% | 0,04 MSEK

2024-12-11 12:10:00 Publication of clinical Phase IIb trial data for the adjuvanted RH5.1 blood-stage malaria vaccine 29,60 SEK | +23,85% | 2,02 MSEK

2024-12-11 10:00:00 Analysguiden Publishes Research Report on ExpreS2ion Biotech with Price Target of SEK 91 29,60 SEK | +23,85% | 2,02 MSEK

2024-12-06 15:00:00 Warrants of series TO 10 were exercised to approximately 69 percent and ExpreS2ion receives approximately SEK 10 million 21,25 SEK | -3,85% | 0,49 MSEK

2024-12-02 16:12:10 ExpreS2ion announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer 19,96 SEK | -4,27% | 0,69 MSEK

2024-12-02 12:45:00 ExpreS2ion publishes video presentations from Biostock Life Science Summit and Analysguiden Stora Aktiedagarna 19,96 SEK | -4,27% | 0,69 MSEK

2024-12-02 09:30:00 Last day of trading in warrants of series TO 10 in Expres2ion Biotech Holding AB is today, 2 December 2024 19,96 SEK | -4,27% | 0,69 MSEK

2024-11-21 08:45:00 ExpreS2ion Biotechnologies: Full commitments from members of ExpreS2ion's Board and Management holding warrants of series TO 10 19,90 SEK | -5,01% | 0,11 MSEK

2024-11-20 08:30:00 ExpreS2ion Biotechnologies: ExpreS2ion announces the start of the exercise period for warrants of series TO 10 20,95 SEK | 0,00% | 0,38 MSEK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

ExpreS2ion Biotech Holding

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden